On the 21st, HanAll Biopharma shot straight to the upper limit (the top of the daily price band) at the start of trading. Buying appears to be pouring in on news that the company's developing drug "imeroprubart" showed meaningful therapeutic effects in a global trial for patients with highly refractory rheumatoid arthritis.
As of 9:40 a.m. on the day, HanAll Biopharma was trading at 50,900 won, up 11,700 won (29.85%) from the previous session.
Earlier the same day, partner Immunovant said on the 20th (local time) that in an interim analysis at week 16 of a trial involving 170 patients with refractory rheumatoid arthritis (D2TRA), the imeroprubart arm recorded an ACR20 response rate of 72.7%, ACR50 of 54.5%, and ACR70 of 35.8%.
It is drawing attention because such improvement in severe symptoms was confirmed in an ultra‑refractory patient group that had used two or more different modern targeted therapies—such as first‑generation DMARDs, anti‑TNF agents, and JAK inhibitors—without seeing effects. On safety, it was reported to have shown generally excellent tolerability with no new abnormal signals.
Jung I-su, an analyst at IBK Securities, said, "IMVT-1402, the core new‑drug pipeline, released clinical data for refractory rheumatoid arthritis earlier than previously expected and demonstrated efficacy that exceeded market expectations," and raised the target price to 73,000 won from 64,000 won.